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was reached for elderly IRPC post-TUR patients with a moderate IPSS. Neoadjuvant AD 3 months+ concomitant external RT was
the most controversial option (SD 1.0)
Conclusions. Meeting the criteria for IRPC does not mean that treatment should be standardized. Until studies providing clear
evidence on this issue are published, these expert recommendations could serve as potential guidelines.
http://dx.doi.org/10.1016/j.rpor.2013.03.473
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Introduction. Recent reports of an association between androgen deprivation therapy (ADT) and increased risk of cardiovascular
events have generated debate on ADT in patients with cardiovascular comorbidities.
Objectives. To describe options recommended by radiation oncologists in the most controversial aspects of treating PC with ADT
in patients with cardiovascular risk factors.
Methods. The ÁGORA project involved 18 oncologists and comprised 4 phases: (1) selection by a panel of experts of the most
controversial aspects in the administration of ADT in patients with a cardiovascular history and PC; (2) selection of the most
relevant published scientiﬁc articles on this subject; (3) preparation of case reports and associated questionnaires; (4) critical
reading of the articles and discussion of the case reports at regional meetings. Therapeutic procedures were classiﬁed as “highly
recommendable”, “recommendable in some cases”, or “not recommendable/not applicable”. The dispersion of the responses
was considered to indicate consensus (SD<0.15) or high variability (SD>0.85).
Results. The panel recommended that, in the absence of solid clinical evidence, patients with high- and very high-risk PC and
a history of severe cardiovascular disease should receive aLHRH in preference to other options. The panel also considered ADT
with aLHRH for 24-36 months combined with RT to be highly recommendable. In patients with intermediate-risk PC and a history
of cardiovascular disease, the panel considered ADT with aLHRH for 6-8 months in combination with RT and not administering
ADT to be highly recommendable approaches.
Conclusions. Speciﬁc studies are necessary to investigate the impact of ADT on cardiovascular mortality in patients who beneﬁt
most from adjuvant ADT in terms of survival. In the absence of such studies, the experts believe that published clinical evidence
on the proven therapeutic beneﬁts of ADT should override concerns about potential cardiovascular toxicity.
http://dx.doi.org/10.1016/j.rpor.2013.03.474
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Introduction. Up to now, commercial atlases for automatic segmentation have been employed successfully in brain and head &
neck sites, for radiation therapy. To our knowledge no prostate atlas has been analyzed. Our objective is to show to what extent
prostate atlas can be used.
Methods. We used an evaluation version of Mimvista, that allows automatic contouring of volumes, by means of a library of 30
patients. For each patient, rectum, bladder, prostate and seminal vesicles were handmade deﬁned, whose deﬁnition was chosen
beforehand. For 10 patients, not included in the library, these organs where delineated by the radiation oncologist. MimVista
softwareusesmutual informationmatchingmetric anddeformation algorithms toﬁt the closest patient in the library to the target
patient, and then copy the contours. We check the accuracy visually, by an average distance between the compared contours,
and a conformality index (ratio of volume of intersection to manual delineated volume)
Results. Despite gas pockets, prostate and rectum scored better than the rest, due to differences in ﬁlling and use of stark contrast
(bladder) and due to the small volume (seminal vesicles). With mild contrast bladder scored at best (2.5mm distance difference).
Yet, for other organs, the average distance between contours could not be lowered under 3mm (5mm average). The time required
for automatic contouring was less than 1min.
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Conclusions. Patient preparation is crucial for accurate automatic delineation. It’s expected that the bigger the number of library
patients the higher the score of the matching. Careful selection of patients to be added to the atlas and adequate contouring by
the radiation oncologist should be made.
http://dx.doi.org/10.1016/j.rpor.2013.03.475
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Introduction. External beam radiotherapy (EBRT) with coadjuvant hormonal therapy (HT) is a reliable alternative to surgery in
patients with locally advanced prostate cancer.
Purpose. To analyze a case of our service and to review the literature on the efﬁcacy and tolerability of bicalutamide versusmedical
castration, coadjuvant to EBRT.
Methods. Retrospective analysis of a clinical case and review of the literature.
Results. 67 years old patient, diagnosed with high-risk prostate adenocarcinoma: prostate-speciﬁc antigen (PSA) = 25.45ng/ml.
Gleason score: 4 + 5 bilateral. Clinical T3a. Perineural invasion. Negative bone scan. CT: seminal vesicle invasion. Treatment
alternatives: Radical surgery vs EBRT+HT. The patient chooses the RTE because he wants to preserve sexual function. Androgen
deprivation options: central action with RHLH analogues vs peripheric action with bicalutamide. The patient selects the second
for the same reason. After 3 months of HT with bicalutamide 150mgr, PSA nadir is 2.13ng/ml. Then get EBRT on a volume
that covers prostate, seminal vesicles and risk iliac lymph nodes, with good tolerance. Proceed with bicalutamide for three
years. Post-EBRT biochemical control: PSA=1.6ng/ml, without signiﬁcant toxicity. After 24 months of follow up, continuing with
bicalutamide, asymptomatic and sexually active. Mild bilateral gynecomastia and breast pain. Local exploration: ﬁbrotic prostate
nodule in the right lobe. PSA<0.03ng/ml. The HT with EBRT shows a signiﬁcant increase in progression-free survival and overall
survival in patients with locally advanced prostate cancer. Bicalutamide with EBRT reduce the risk of death at similar rates to
medical castration (25–30%). Compared with medical castration, bicalutamide monotherapy provides a higher quality of life and
tolerance, and lower rates of hot ﬂashes, although gynecomastia and breast pain have a higher incidence.
Conclusions. Bicalutamidemonotherapy should be considered as a valid alternative in the hormonal treatment of locally advanced
prostate cancer.
http://dx.doi.org/10.1016/j.rpor.2013.03.476
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Introduction. Brachytherapy for prostate cancer has established itself in recent years as the ﬁrst line treatment in selected patients
with localized prostate cancer.
Objectives. To analyze characteristics and biochemical control of patients treated with 125I brachytherapy since the introduction
of the technique in our department.
Materials and methods. Between July-07 and January-13 a total of 144 implants have been performed. For the study we analyzed
retrospectively 100 patients (minimum follow-up 1 year). We analyzed age, neoadjuvant hormonal therapy, PSA, Gleason score,
T stage, risk group, number and time to nadir and biochemical control (Phoenix criteria). Statistical analysis: We performed a
descriptive study calculating mean and standard deviation for quantitative variables and absolute frequencies and percentages
for qualitative variables. We performed a survival analysis using Kaplan–Meier method to calculate the biochemical control.
Results. Mean age was 64.6±6.6 years (49–75). 17% had started androgen deprivation therapy. Mean PSA was 5.8±1.7ng/ml
(2.4–9.7). Gleason score 6was themost frequent (93%), followed by 5 (4%) and 7 (2%). Distribution by stages: T1c (96%), followed T2a
(4%). Risk group: low (98%), intermediate (2%). Mean nadir was 0.74±0.93ng/ml (0.0–5.8) and median time to reach it 22.2±15.3
months (3.7–57). 6 patients had biochemical recurrence. With a median follow up of 36.4 months (12–64), biochemical control at
2 and 4 years was 97.3% and 86.2% respectively.
Conclusions. 125I brachytherapy as radical treatment in selected patients with localized prostate carcinoma achieves optimal
results in terms of biochemical control. The results obtained in our series are equivalent to those described in the literature.
http://dx.doi.org/10.1016/j.rpor.2013.03.477
